Definium Therapeutics: Pay

Definium Therapeutics paid its 2 named executives $9.1M in total in FY2025 (Dec).

Pay$100 in the stock at the end of FY21 → $34
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Brandi L. RobertsChief Financial Officer
FY2025 (Dec)
1 year
Daniel Karlin, M.D.Chief Medical Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years
Robert BarrowChief Executive Officer
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
3 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 6 peers with pay on file was $5.9M. CEO pay of Definium Therapeutics for that year is not on file.

  1. 1Praxis Precision Medicines
  2. 2MeiraGTx Holdings
  3. 3Arvinas
  4. 4Solid Biosciences
  5. 5Trevi Therapeutics
  6. 6Fulcrum Therapeutics
  7. 7Definium TherapeuticsNot disclosed
  8. 8Alector, Inc.Not disclosed
  9. 9Anavex Life SciencesNot disclosed
  10. 10Annexon, Inc.Not disclosed
  11. 11AtaiBeckley Inc.Not disclosed
  12. 12Compass Pathways plcNot disclosed
  13. 13Humacyte, Inc.Not disclosed
  14. 14Kalvista Pharmaceuticals, Inc.Not disclosed
  15. 15Larimar Therapeutics, Inc.Not disclosed
  16. 16LeonaBio, Inc. (f/k/a Athira Pharma)Not disclosed
  17. 17Lineage Cell Therapeutics, Inc.Not disclosed
  18. 18Neumora Therapeutics, Inc.Not disclosed
  19. 19Relmada Therapeutics, Inc.Not disclosed
  20. 20Stoke TherapeuticsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.